Oyster Point Pharma Submits a Phase 2 Clinical Trial Protocol to Evaluate OC-01 Nasal Spray for Neurotrophic Keratitis (NK)
01 déc. 2020 16h01 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma to Attend the Piper Sandler 32nd Annual Virtual Healthcare Conference
25 nov. 2020 09h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma Announces Clinical Data Presentations on OC-01 Nasal Spray for Dry Eye Disease at the American Academy of Ophthalmology 2020 Virtual Annual Meeting
13 nov. 2020 07h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma Reports Third Quarter 2020 Financial Results and Recent Business Highlights
05 nov. 2020 16h01 HE
|
Oyster Point Pharma, Inc.
OC-01 New Drug Application (NDA) Submission to U.S. Food and Drug Administration (FDA) for Signs and Symptoms of Dry Eye Disease Remains on Track for Q4 2020OC-01 Investigational New Drug (IND)...
Oyster Point Pharma to Report Third Quarter 2020 Financial Results on November 5, 2020
29 oct. 2020 16h01 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma Announces Board of Directors Leadership Changes and New Appointment as the Company Advances into Next Phase of Growth
08 oct. 2020 16h01 HE
|
Oyster Point Pharma, Inc.
Ali Behbahani, M.D. takes on role of Chairperson of the Board Michael G. Atieh joins the Board of Directors as Chairperson of the Audit Committee PRINCETON, N.J., Oct. 08, 2020 (GLOBE NEWSWIRE)...
Oyster Point Pharma to Present at the Morgan Stanley Virtual 18th Annual Global Healthcare Conference
11 sept. 2020 08h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma Reports Second Quarter 2020 Financial Results and Recent Business Highlights
05 août 2020 07h00 HE
|
Oyster Point Pharma, Inc.
OC-01 New Drug Application (NDA) Submission to U.S. Food and Drug Administration (FDA) for Signs and Symptoms of Dry Eye Disease (DED) Planned for Q4 2020Cash and Cash Equivalents of $226.7 million as...
Oyster Point Pharma to Report Second Quarter 2020 Financial Results on August 5, 2020
31 juil. 2020 16h01 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., July 31, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Oyster Point Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
19 mai 2020 18h08 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., May 19, 2020 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class...